# Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis

> **NCT04895917** · PHASE2 · TERMINATED · sponsor: **Fondazione IRCCS Policlinico San Matteo di Pavia** · enrollment: 27 (actual)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** daratumumab and pomalidomide

## Key facts

- **NCT ID:** NCT04895917
- **Lead sponsor:** Fondazione IRCCS Policlinico San Matteo di Pavia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-23
- **Primary completion:** 2024-12-18
- **Final completion:** 2025-01-15
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** low patient enrollment rate
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04895917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04895917, "Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04895917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*